Curis (NASDAQ:CRIS) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.
Curis stock opened at $1.81 on Tuesday. Curis has a 52 week low of $0.60 and a 52 week high of $2.90. The business’s 50 day moving average price is $2.07.
Curis (NASDAQ:CRIS) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). Curis had a negative return on equity of 729.52% and a negative net margin of 314.07%. The firm had revenue of $2.09 million for the quarter.
Several institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new position in shares of Curis during the 2nd quarter worth approximately $40,000. Geode Capital Management LLC increased its stake in shares of Curis by 21.5% during the 4th quarter. Geode Capital Management LLC now owns 218,803 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 38,789 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Curis by 196.7% during the 4th quarter. Bank of New York Mellon Corp now owns 66,588 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 44,147 shares during the last quarter. Finally, Fosun International Ltd increased its stake in shares of Curis by 97.4% during the 1st quarter. Fosun International Ltd now owns 396,869 shares of the biotechnology company’s stock worth $762,000 after purchasing an additional 195,783 shares during the last quarter. 22.47% of the stock is currently owned by hedge funds and other institutional investors.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.